Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study.
ABCB1
acute myeloid leukemia
drug resistance
gene expression
prognosis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 Sep 2019
06 Sep 2019
Historique:
received:
15
07
2019
revised:
23
08
2019
accepted:
03
09
2019
entrez:
11
9
2019
pubmed:
11
9
2019
medline:
11
9
2019
Statut:
epublish
Résumé
ABCB1 is a member of the ATP binding cassette transporter family and high ABCB1 activity is considered as a poor prognostic factor in acute myeloid leukemia (AML) treated with intensive chemotherapy, its direct relation with drug resistance remains unclear. We evaluated ABCB1 activity in relation with clinical parameters and treatment response to standard chemotherapy in 321 patients with de novo AML. We assessed multiple clinical relationships of ABCB1 activity-ex vivo drug resistance, gene expression, and the ABCB1 inhibitor quinine were evaluated. ABCB1 activity was observed in 58% of AML and was linked to low white blood cell count, high expression of CD34, absence of
Identifiants
pubmed: 31500210
pii: cancers11091323
doi: 10.3390/cancers11091323
pmc: PMC6770064
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fondation de France
ID : Comite Leucemie 2009
Organisme : Institut National Du Cancer
ID : DHOS 2009
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Pharmacogenomics. 2013 Jan;14(1):17-23
pubmed: 23252945
Blood. 2007 May 15;109(10):4168-70
pubmed: 17227830
Blood. 2003 Aug 15;102(4):1202-10
pubmed: 12663440
Pharmacol Rev. 1990 Sep;42(3):155-99
pubmed: 2217530
Blood. 1995 Apr 15;85(8):2147-53
pubmed: 7536492
Blood. 2010 Sep 2;116(9):1413-21
pubmed: 20522709
Curr Opin Hematol. 1998 Jul;5(4):287-91
pubmed: 9747635
Blood. 2010 Jan 21;115(3):453-74
pubmed: 19880497
Blood. 1996 Aug 15;88(4):1198-205
pubmed: 8695837
Blood. 1998 Jun 15;91(12):4480-8
pubmed: 9616142
Drug Resist Updat. 2012 Feb-Apr;15(1-2):62-9
pubmed: 22409994
Leukemia. 2017 Mar;31(3):555-564
pubmed: 27686867
Blood. 1992 Jan 15;79(2):473-6
pubmed: 1370388
N Engl J Med. 2004 Aug 5;351(6):533-42
pubmed: 15295046
Ann Hematol. 2007 May;86(5):329-37
pubmed: 17340137
Blood Rev. 2013 Sep;27(5):209-16
pubmed: 23871358
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Haematologica. 2012 Feb;97(2):241-5
pubmed: 22058196
J Clin Oncol. 2004 Nov 1;22(21):4290-301
pubmed: 15514371
Lancet. 2012 Apr 21;379(9825):1508-16
pubmed: 22482940
Br J Haematol. 1998 Sep;102(4):1015-24
pubmed: 9734653
Blood. 2003 Sep 1;102(5):1613-8
pubmed: 12750167
Blood. 2005 Oct 15;106(8):2646-54
pubmed: 15994288
Leukemia. 2011 May;25(5):792-9
pubmed: 21274000
Nature. 2016 Dec 15;540(7633):433-437
pubmed: 27926740
Blood. 2001 Dec 1;98(12):3212-20
pubmed: 11719356
J Natl Cancer Inst. 1991 May 15;83(10):708-12
pubmed: 2023272
Nat Rev Cancer. 2018 Jul;18(7):452-464
pubmed: 29643473
J Clin Oncol. 2004 Mar 15;22(6):1078-86
pubmed: 15020609
Blood. 1991 Aug 1;78(3):586-92
pubmed: 1859877
Blood. 2001 Aug 15;98(4):988-94
pubmed: 11493443